(Yicai Global) Nov. 20 -- Amoy  Diagnostics has gotten the green light to sell the country's first  next-generation sequencing gene testing products in China. 

Amoy, also known as AmoyDx, received the  approval from the National Drug Administration for its human 10-gene  mutation combined detection kit, which is used for diagnosing  non-small-cell lung cancer and colorectal cancer, the Xiamen-based firm  said in a statement today.

The firm's [SHE: 300685] share price rose  more than 2 percent to CNY50.71 at 1.30 p.m. yesterday. The stock has  fallen slightly today to close at CNY49.98.

Editor: Emmi Laine